Opinion

Will the Industry Rise to the Occasion?

July 09, 2020

Pharmaceutical Executive

Gilead's pricing of COVID drug remdesivir is a reminder of pharma's tenuous path forward as it seeks a more holistic image makeover.

Vaccine “Hesitancy” Threatens COVID Immunization Efforts

June 01, 2020

While scientists are striving to discover and produce safe and effective vaccines to halt the coronovirus outbreak, anti-vacciners are revving up misinformation campaigns.

Master the Science of Success

May 01, 2020

Pharmaceutical Executive

Welcome to the new look and branding of Pharmaceutical Executive-reimagined to better reflect you, our audience, and expand on the content you've long trusted us to deliver.

A Bold Deal Could Help Trump Administration End HIV in America

August 13, 2019

The US could theoretically treat every single American living with HIV without spending an extra dollar on drugs. And President Trump can broker a deal to do it, write Anil Soni and Ya’ir Aizenman.

Time is Running Out for Pharma to Change Course

April 01, 2019

Outside of raising prices, pharma can generate new revenue from just three other sources, write Tom Kottler.

Innovating Around Innovation

September 01, 2011

Pharmaceutical Executive

Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.

Get Back in the Box!

September 01, 2011

Pharmaceutical Executive

Despite the gloom, most forecasts show the US will stay atop the industry in profits for at least the next generation of products.

Giving Press Releases New Legs

August 01, 2011

Pharmaceutical Executive

Social media now gives companies a plethora of creative ways to digitally spread recent company news and keep customers informed

Europe in HTA Gridlock

August 01, 2011

Pharmaceutical Executive

HTAs are gridlocked by diverse national requirements, a lack of alignment on processes, and even on the value of their outcomes.

UK Stakeholders Have Their Say on Value-Based Pricing

May 01, 2011

Pharmaceutical Executive

The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance